Submit Deal

Announced

27 Mar 2024

Completed

27 Mar 2024

Bpifrance and Pemberton completed the investment in Juvisé Pharmaceuticals.

Synopsis

Bpifrance, a public sector investment bank, and Pemberton, a debt manager investing in non-investment grade debt, completed the investment in Juvisé Pharmaceuticals, a pharmaceutical company, specialized in manufacturing and marketing ethical brands. Financial terms were not disclosed.

Principals

target

Juvise Pharmaceuticals

bidder

Pemberton Capital Advisors

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Sort

Seller Team (7)

frédéric mascha

Founder and President at JUVISE PHARMACEUTICALS

Manager

target

Deal

n/a

Total Value

anne robert

Partner at Bredin Prat

Lawyer

target

Deals

£ 54.37 B

Total Value

paul cauchin

Associate at Bredin Prat

Lawyer

target

Deals

£ 7.53 B

Total Value

olivier assant

Partner at Bredin Prat

Lawyer

target

Deals

£ 41.17 B

Total Value

jerome vincent

Associate at Bredin Prat

Lawyer

target

Deals

£ 30.71 B

Total Value

thomas delacour

Associate at Bredin Prat

Lawyer

target

Deals

£ 1.20 B

Total Value

jean-baptiste frantz

Partner at Bredin Prat

Lawyer

target

Deals

£ 27.19 B

Total Value

Bidder Team (2)

symon drake-brockman

Co-Founder and Managing Partner at PEMBERTON CAPITAL ADVISORS LLP

Manager

bidder

Deal

n/a

Total Value

nicolas dufourcq

CEO at BPIFRANCE INVESTISSEMENT

Manager

bidder

Deals

£ 36.59 B

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy